Eterna Therapeutics Inc
ERNA
查看详细走势图
0.376USD
-0.304-44.66%
收盘 02/06, 16:00（美东）报价延迟15分钟
2.95M总市值
0.01市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-44.66%
5天
-69.16%
1月
-70.37%
6月
-77.60%
今年开始到现在
-68.64%
1年
-92.62%
查看详细走势图
TradingKey Eterna Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Eterna Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名222/392位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Eterna Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Eterna Therapeutics Inc亮点
亮点风险
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
业绩增长期
公司处于发展阶段，最新年度总收入582.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入582.00K美元
估值高估
公司最新PE估值0.01，处于3年历史高位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值35.92K
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Eterna Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Eterna Therapeutics Inc简介
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
公司代码ERNA
公司Eterna Therapeutics Inc
CEOLuther (Sanjeev)
网址https://www.ernexatx.com/
相关品种
